Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ferrer Announces Best-in-Class Results in Phase I for Lorediplon in Insomnia

Published: Wednesday, February 15, 2012
Last Updated: Tuesday, February 14, 2012
Bookmark and Share
Ferrer now seeking development partners for Lorediplon that has demonstrated a highly promising efficacy, safety and tolerability profile.

Ferrer has announced that it has completed phase I clinical trials of Lorediplon in insomnia. The trials demonstrated the orally available compound has a best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to market leader zolpidem.

The pharmacodynamic effects of a single oral administration of Lorediplon (at 1mg, 5mg and 10mg doses), zolpidem (10mg) and placebo, were assessed in 34 healthy adult subjects employing a phase advanced model of insomnia, in which subjects retire to bed five hours earlier than normal and are required to stay there until early morning.

In this model Lorediplon demonstrated dose related clinical benefits in measured sleep parameters that were either comparable to or exceeded zolpidem, in terms of the duration and quality of sleep that subjects achieved.

Lorediplon was safe and well tolerated, with no residual effects observed up to 14 hours after dosing.

In addition, Lorediplon has proven safe and well tolerated in the 129 subjects involved in all Phase I clinical studies.

"Insomnia remains a common sleep disorder that has both a significant impact on an individual's quality of life and broader impact on society, in terms of reduced productivity and associated healthcare costs," says Antonio Guglietta, R&D director at Ferrer.

Guglietta continued, "Lorediplon is the first product to enter clinical trials from our CNS discovery program, the aim of which is to deliver differentiated products targeting underserved needs in insomnia and related sleep disorders. Having demonstrated the clinical benefits, safety and tolerability of Lorediplon, we are actively seeking partners to further the worldwide clinical development and commercialization of Lorediplon."

The emerging clinical and preclinical profile of orally available Lorediplon supports further development as a potential best-in-class non-benzodiazapine (BZD) treatment for sleep insomnia, both in terms of efficacy (improved sleep maintenance and quality), tolerability and the absence of next-day residual effects associated with other treatments in this class.

Lorediplon is the subject of a number of granted and pending patents and is available for further development and commercialization worldwide from Ferrer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Absorption, Tolerability and Safety Study for Novel Antibacterial Compound Completed
Ferrer announced it has successfully completed a clinical trial, in adult and juvenile patients with impetigo, involving Ozenoxacin formulated as a topical treatment.
Friday, October 19, 2012
Scientific News
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
Muscles on-a-Chip
This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!